Zastaprazan (JP-1366) Shows High Ulcer Healing Rates in Phase 3 Trial | Onconic Therapeutics

New research published in the international journal Gut and Liver details promising results from a Phase 3 clinical trial of Zastaprazan (JP-1366), a next-generation acid secretion inhibitor, in patients with gastric ulcers. The study, conducted across 39 medical institutions, demonstrates high ulcer healing rates and a favorable safety profile for the medication.

High Healing Rates Observed in Clinical Trial

The randomized, double-blind, active-controlled trial involved 329 patients with gastric ulcers. Participants received 20 mg of Zastaprazan for up to eight weeks, allowing researchers to comprehensively evaluate both its efficacy and safety. After eight weeks of treatment, endoscopic ulcer healing was confirmed in 100% of patients in all Zastaprazan treatment groups.

Did You Know? The clinical trial involved 39 medical institutions and 329 patients with gastric ulcers.

Notably, a high healing rate of 93.84% was observed as early as the four-week mark. Researchers attribute this rapid improvement to Zastaprazan’s ability to quickly and consistently suppress stomach acid. The study also showed a significant reduction in ulcer size, with the average ulcer decreasing to less than 1mm in just four weeks, and most ulcers unobservable by the eight-week point.

Beyond Symptom Management

These findings suggest Zastaprazan doesn’t just manage symptoms, but actively promotes mucosal healing. Zastaprazan previously secured approval for the treatment of gastric ulcers, and this publication provides further academic validation of its high healing rates and safety.

Expert Insight: The consistently high healing rates observed throughout the trial, particularly the significant improvement within the first four weeks, suggest Zastaprazan could represent a valuable advancement in the treatment of gastric ulcers, potentially improving patient outcomes and quality of life.

Future Research and Potential Expansion

Onconic Therapeutics, the company behind Zastaprazan, plans to strategically expand its use in the treatment of gastric ulcers based on these results. Phase 3 clinical trials are currently underway to explore its potential in treating non-erosive gastroesophageal reflux disease (GERD) and for the prevention of NSAID-induced ulcers. Further research is also planned to assess Zastaprazan’s effectiveness in other acid-related conditions.

According to an Onconic Therapeutics representative, the published research confirms Zastaprazan’s performance and safety in a large-scale study, and the company anticipates continued revenue growth as its clinical role expands to include both treatment and preventative applications.

Frequently Asked Questions

What was the primary goal of the clinical trial?

The primary goal of the clinical trial was to evaluate the efficacy and safety of Zastaprazan in patients with gastric ulcers.

How long did the clinical trial last?

Patients in the clinical trial received Zastaprazan for up to eight weeks.

What other conditions is Zastaprazan being investigated for?

Zastaprazan is currently being investigated for the treatment of non-erosive gastroesophageal reflux disease (GERD) and for the prevention of NSAID-induced ulcers.

As research continues and potential new applications are explored, how might advancements in acid secretion inhibitors like Zastaprazan change the landscape of gastrointestinal health?